Ionis Pharmaceuticals, Inc.
Compositions for Modulating Ataxin 2 Expression
Last updated:
Abstract:
Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.
Status:
Application
Type:
Utility
Filling date:
4 Aug 2021
Issue date:
23 Jun 2022